Drugs / DASOLAMPANEL ETIBUTIL
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00790790 | Nov 2008 → Jan 2010 | osteoarthritis, knee | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00785577 | Nov 2008 → May 2010 | diabetic neuropathy | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DASOLAMPANEL ETIBUTIL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107328 ↗ |
| Known as | DASOLAMPANEL ETIBUTIL TOSYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107328 ↗ |
| Known as | LY545694 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00790790 ↗ |
| Action | Inhibit | “Metabotropic glutamate receptor 5 antagonist” CHEMBL2107328 ↗1“LY545694, an iGluR5 Antagonist” NCT00785577 ↗ |
| Modality | Small molecule | — CHEMBL2107328 ↗ |
| Route | Oral | “LY545694 21 mg BID po for 1 week” NCT00785577 ↗ |
| Target | GRM5 | “Metabotropic glutamate receptor 5 antagonist” CHEMBL2107328 ↗ |